## Review setup
- **Input scope** Full manuscript text (abstract, introduction, methodology, results, discussion, conclusion) as provided
- **Assessment boundary** Scientific soundness, methodological rigor, validity of claims relative to evidence presented, and alignment with Nature-style criteria
- **Shared manuscript claim summary** The authors report a computational study investigating halogenated phenazine compounds as inhibitors of the Staphylococcus aureus AgrA LytTR domain. Using molecular docking, 200 ns molecular dynamics simulations, computational mutagenesis, and MM-PBSA binding free energy calculations, they claim these compounds bind at the DNA-binding interface, disrupt key salt bridges (His174-Glu163, His174-Glu226), induce conformational changes that reduce DNA binding affinity, and thereby explain the experimentally observed antibiofilm activity of these compounds.
- **Visible evidence base** Abstract, full methodology section, results section with descriptions of Figures 1-11 and Tables 1-2, discussion, conclusion, data availability statement
- **Missing materials affecting confidence** Figures 1-11 and Tables 1-2 are referenced but not visible; Supporting Information (Figures S1-S7) not provided; no experimental validation data; no statistical analysis details; no convergence criteria for MD simulations; no force field validation details

## Reviewer

### Overall assessment
This manuscript presents a purely computational investigation of phenazine-based inhibitors targeting the AgrA LytTR domain of S. aureus. The topic is of potential interest given the clinical burden of biofilm-associated infections and the need for novel anti-virulence strategies. However, the study has substantial methodological weaknesses that undermine the strength of the conclusions drawn. The binding free energy values reported (e.g., -80.75 kcal/mol for the apo form) are implausibly large for a protein-DNA interaction and suggest a fundamental issue with the calculation methodology or interpretation. The manuscript also conflates "binding energy" with "binding free energy" and omits entropic contributions while simultaneously reporting ΔGbind values. The computational mutagenesis section is underdeveloped, lacking validation against experimental data despite the authors acknowledging prior experimental work. The claim that the compounds "effectively inhibit biofilm formation" is not supported by any direct experimental evidence in this study. The manuscript would benefit from substantial revision, additional analyses, and more cautious interpretation of results.

### Who would be interested in the results, and why
Researchers working on anti-virulence strategies against S. aureus, particularly those focused on the Agr quorum-sensing system, would find this topic relevant. Computational chemists and structural biologists interested in the LytTR domain family of transcription factors may also find the docking and MD simulation data of interest. However, the lack of experimental validation limits the audience to those interested in computational predictions as a starting point for further investigation. The potential clinical relevance of antibiofilm agents targeting AgrA would attract interest from infectious disease researchers, but the purely computational nature of the study without experimental follow-up substantially narrows the immediate applicability.

### Major Strengths
1. The study addresses a clinically relevant problem: biofilm formation in S. aureus and the need for novel therapeutic strategies targeting virulence regulators.
2. The authors employ a multi-method computational approach (docking, MD, mutagenesis, binding energy calculations) which, in principle, could provide complementary insights.
3. The focus on the AgrA LytTR domain as a drug target is well justified by prior literature establishing its role in virulence regulation.
4. The authors correctly identify key DNA-binding residues (Arg233, Asn201, His169) based on prior structural and mutational studies.
5. The discussion of salt bridge interactions and their potential disruption by ligand binding is mechanistically plausible and connects to known structural features of the protein.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness of binding energy calculations
- **Claim pointer** The authors report ΔGbind values of -80.75 kcal/mol for the apo AgrA-DNA complex and -113.84, -115.23, and -112.28 kcal/mol for C7, HP-14, and HP, respectively, and claim these represent binding free energies.
- **Evidence pointer** Section 3.8, Table 2
- **Concern** The reported binding free energy values are physically implausible. A protein-DNA interaction with a ΔGbind of -80.75 kcal/mol corresponds to an equilibrium dissociation constant on the order of 10^-59 M, which is many orders of magnitude stronger than any known biological interaction. Typical protein-DNA binding free energies range from approximately -8 to -15 kcal/mol. The MM-PBSA method, while approximate, should not produce values of this magnitude unless there is a fundamental error in the calculation setup, such as incorrect treatment of the apo state reference, double-counting of interaction energies, or failure to properly account for the DNA as part of the receptor in the bound state. The authors also state that the entropic term was omitted, yet they report these values as "binding free energy" (ΔGbind), which is thermodynamically incorrect. The term "binding energy" (Ebinding) is used in the methods, but the results section reports ΔGbind, creating confusion about what was actually calculated.
- **Why it matters** The central quantitative claim of the study, that these compounds enhance binding affinity relative to the apo form, rests entirely on these calculations. If the absolute values are incorrect, the relative ranking and the conclusion that the compounds "enhance binding affinity" cannot be trusted. This undermines the primary conclusion of the manuscript.
- **Resolution test** The authors must clarify the exact calculation protocol, report the individual energy components (van der Waals, electrostatic, polar solvation, nonpolar solvation) for each system, and explain why the absolute values are so large. They should benchmark their MM-PBSA protocol against a known protein-DNA system with experimentally determined binding affinity. If entropic contributions are omitted, the values should be reported as enthalpy changes (ΔH), not free energies (ΔG), and the text should be corrected accordingly.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Validity of computational mutagenesis conclusions
- **Claim pointer** The authors state that mutating Arg233, Asn201, and His169 to alanine (triple mutant) resulted in loss of DNA affinity at ~3.2 ns, and that this supports the importance of these residues for DNA binding.
- **Evidence pointer** Section 3.6, Figure 10, Figure S5
- **Concern** The computational mutagenesis experiment is described only briefly. The authors mutated three residues simultaneously to alanine and measured the distance between protein and DNA over time. However, no details are provided on how the mutations were introduced, whether the system was re-equilibrated after mutation, how the "distance between protein and DNA" was defined, or what threshold was used to define "loss of affinity." The observation that the triple mutant loses DNA contact at 3.2 ns in a single simulation is weak evidence for the importance of these residues, as a single trajectory cannot provide statistically meaningful conclusions. The authors acknowledge prior experimental work by Nicod et al. but do not directly compare their computational results to those experimental findings. Furthermore, the claim that "the compounds can hinder the function of AgrA by blocking AgrA binding to DNA" is presented as a conclusion, but the computational mutagenesis was performed on the unliganded protein-DNA complex, not on the ligand-bound complex.
- **Why it matters** The computational mutagenesis is presented as a key validation of the mechanism of action. If the methodology is not robust or the results are not compared to experimental data, the mechanistic claim is unsupported. The distinction between the effect of mutations on DNA binding and the effect of ligand binding on DNA binding is critical and appears to be conflated.
- **Resolution test** The authors should provide detailed methodology for the mutagenesis protocol, run multiple independent simulations (at least 3 replicates) for both wild-type and mutant systems, define clear metrics for DNA binding affinity (e.g., contact maps, hydrogen bond occupancy, binding free energy calculations for the mutant), and directly compare their computational predictions to the experimental results of Nicod et al. The discussion should clearly separate the effects of mutations from the effects of ligand binding.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Overinterpretation of computational results as experimental validation
- **Claim pointer** The authors state that "the halogenated phenazine compounds effectively inhibit biofilm formation by targeting AgrA, disrupting its DNA-binding function" and that their results "explain the molecular basis of HP antibiofilm activity from an in vitro study."
- **Evidence pointer** Abstract, Section 4 (Discussion), Section 5 (Conclusion)
- **Concern** This manuscript contains no experimental data. The claim that the compounds "effectively inhibit biofilm formation" is presented as a finding of this study, but no biofilm inhibition assays, bacterial growth assays, or any in vitro experiments were performed. The authors reference the experimental work of Huigens, Abouelhassan, and Yang for the antibiofilm activity, but the current study only provides computational predictions. The leap from computational binding predictions to a statement of effective inhibition is not justified. Additionally, the authors do not address potential limitations of the computational approach, such as the lack of explicit membrane environments, the absence of post-translational modifications, or the simplified treatment of solvation.
- **Why it matters** The conclusion overstates what the evidence supports. Nature-style manuscripts must clearly distinguish between computational predictions and experimental validation. The current phrasing could mislead readers into believing that experimental confirmation was performed in this study.
- **Resolution test** The authors should revise all claims to clearly state that these are computational predictions that require experimental validation. Phrases such as "effectively inhibit" should be replaced with "are predicted to inhibit" or "may inhibit." The discussion should include a clear statement of limitations and the need for experimental follow-up.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Insufficient methodological detail for reproducibility
- **Claim pointer** The authors describe using molecular docking with AutoDock Vina in PyRx, MD simulations with GROMACS, and MM-PBSA calculations, but provide limited details on parameters, validation, and analysis protocols.
- **Evidence pointer** Section 2 (Methodology)
- **Concern** The methodology section lacks critical details required for reproducibility. For example: (a) the specific version of AutoDock Vina and PyRx is not stated; (b) the search space for docking is not defined; (c) the protonation states of the protein and ligands are not described; (d) the force field parameters for the ligands are not specified (CGenFF was mentioned, but the version and validation are not described); (e) the equilibration protocol is described only briefly; (f) the number of MD replicates is not stated; (g) the MM-PBSA calculation parameters (e.g., grid spacing, dielectric constants, number of frames used) are not provided; (h) the clustering algorithm parameters are not fully specified. Without these details, the study cannot be reproduced or properly evaluated by other researchers.
- **Why it matters** Reproducibility is a cornerstone of scientific publishing. The lack of methodological detail prevents other researchers from building on this work or verifying the results. This is particularly important for computational studies where results can be highly sensitive to parameter choices.
- **Resolution test** The authors should provide a complete description of all computational parameters, including software versions, force field versions, docking grid dimensions, MD simulation parameters, MM-PBSA settings, and analysis protocols. Consider providing input files as supplementary material.

- **Concern ID** R1-M5
- **Severity** Major
- **Blocking** No
- **Axis** Inconsistent and incomplete reporting of results
- **Claim pointer** The results section describes findings from Figures 1-11 and Tables 1-2, but the actual figures and tables are not visible in the provided material. The text also contains inconsistencies, such as referring to "C1-C8" in Section 3.3 but "C1-C7" elsewhere, and the abstract mentions "C1 to C7, HP, and HP-14" while the results mention "C1-C8."
- **Evidence pointer** Section 3 (Results), Table 1, Table 2
- **Concern** The manuscript text references figures and tables that are not available for review, making it impossible to verify the claims made. Additionally, there are inconsistencies in the naming of compounds (C1-C7 vs. C1-C8) that need clarification. The results section also lacks quantitative details for many claims. For example, the RMSD values are described qualitatively ("stable," "higher deviation") without providing numerical values or error bars. The MM-PBSA results are presented as a single table without statistical analysis or error estimates.
- **Why it matters** The inability to verify the results against the actual figures and tables, combined with inconsistencies in compound naming, reduces confidence in the reliability of the reported findings. Nature-style manuscripts require clear, consistent, and verifiable reporting of results.
- **Resolution test** The authors should ensure all figures and tables are included and properly referenced. They should clarify the compound naming scheme and ensure consistency throughout the manuscript. Quantitative results should include numerical values with appropriate statistical measures (e.g., mean ± standard deviation from multiple replicates).

- **Concern ID** R1-M5
- **Severity** Major
- **Blocking** No
- **Axis** Inconsistent and incomplete reporting of results
- **Claim pointer** The results section describes findings from Figures 1-11 and Tables 1-2, but the actual figures and tables are not visible in the provided material. The text also contains inconsistencies, such as referring to "C1-C8" in Section 3.3 but "C1-C7" elsewhere, and the abstract mentions "C1 to C7, HP, and HP-14" while the results mention "C1-C8."
- **Evidence pointer** Section 3 (Results), Table 1, Table 2
- **Concern** The manuscript text references figures and tables that are not available for review, making it impossible to verify the claims made. Additionally, there are inconsistencies in the naming of compounds (C1-C7 vs. C1-C8) that need clarification. The results section also lacks quantitative details for many claims. For example, the RMSD values are described qualitatively ("stable," "higher deviation") without providing numerical values or error bars. The MM-PBSA results are presented as a single table without statistical analysis or error estimates.
- **Why it matters** The inability to verify the results against the actual figures and tables, combined with inconsistencies in compound naming, reduces confidence in the reliability of the reported findings. Nature-style manuscripts require clear, consistent, and verifiable reporting of results.
- **Resolution test** The authors should ensure all figures and tables are included and properly referenced. They should clarify the compound naming scheme and ensure consistency throughout the manuscript. Quantitative results should include numerical values with appropriate statistical measures (e.g., mean ± standard deviation from multiple replicates).

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity of terminology
- **Affected element** Abstract, Section 3.8
- **Evidence pointer** Abstract, Table 2
- **Issue** The terms "binding energy," "binding free energy," and "ΔGbind" are used interchangeably throughout the manuscript. These are thermodynamically distinct quantities, and the MM-PBSA method typically estimates enthalpy or free energy depending on whether entropic contributions are included.
- **Required correction** Use consistent terminology throughout. If entropic contributions are omitted, use "binding enthalpy" or "interaction energy" rather than "binding free energy" or "ΔGbind."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Figure quality and accessibility
- **Affected element** Figures 1-11
- **Evidence pointer** Section 3
- **Issue** The figures are not visible in the provided material, and the text descriptions are insufficient to evaluate the quality of the data presentation. Additionally, the manuscript does not describe the color schemes, labels, or units used in the figures.
- **Required correction** Ensure all figures are high-resolution, properly labeled, and include clear legends. Add detailed figure captions describing the data presented and the methods used to generate each figure.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Literature context
- **Affected element** Introduction, Discussion
- **Evidence pointer** Section 1, Section 4
- **Issue** The introduction and discussion reference prior work on AgrA inhibitors and phenazine compounds, but the literature context is somewhat limited. The authors do not discuss alternative computational studies of AgrA or compare their findings to other proposed inhibitors beyond savirin.
- **Required correction** Expand the discussion to include a broader comparison with other computational and experimental studies targeting AgrA or the LytTR domain family, and clearly state what is novel about this study relative to prior work.

- **Concern ID** R1-m4
- **Severity** Minor
- **Axis** Statistical rigor
- **Affected element** Section 3.4, Section 3.8
- **Evidence pointer** Figure 3, Table 2
- **Issue** The manuscript reports RMSD values and binding energies without statistical analysis. It is unclear whether multiple independent MD simulations were performed and whether the reported values represent single trajectories or averages.
- **Required correction** Report the number of independent simulations performed, provide mean and standard deviation values where appropriate, and state whether the reported results are representative of a single trajectory or an ensemble average.

- **Concern ID** R1-m5
- **Severity** Minor
- **Axis** Data availability
- **Affected element** Data Availability Statement
- **Evidence pointer** Data Availability Statement
- **Issue** The data availability statement claims that all data are included in the article, but the figures and tables are not visible in the provided material, and no input files, topology files, or analysis scripts are provided.
- **Required correction** Provide the actual data files, including PDB structures, ligand coordinates, MD parameter files, and analysis scripts, either as supplementary material or through a public repository.

### Technical failings that need to be addressed before the case is established
1. The MM-PBSA binding free energy values are physically implausible and must be recalculated or reinterpreted (R1-M1).
2. The computational mutagenesis methodology is insufficiently described and lacks statistical power (R1-M2).
3. The manuscript overstates conclusions by presenting computational predictions as established findings (R1-M3).
4. The methodology lacks sufficient detail for reproducibility (R1-M4).
5. The results are incompletely reported, with figures and tables not visible and quantitative details missing (R1-M5).

### Assessment against Nature-style criteria
**Originality:** The application of phenazine scaffolds to target the AgrA LytTR domain is a reasonable extension of prior work, but the approach is not conceptually novel. Computational docking and MD studies of AgrA inhibitors have been reported previously, and the phenazine compounds themselves were identified in prior experimental studies. The manuscript does not introduce a new methodology or a fundamentally new concept.

**Scientific importance:** The problem addressed (biofilm formation in S. aureus) is clinically important, and AgrA is a validated target. However, the study is purely computational and does not provide experimental validation. The importance of the findings is therefore limited to generating hypotheses that require experimental testing. The manuscript does not demonstrate that these compounds are more effective or more specific than existing AgrA inhibitors.

**Interdisciplinary readership:** The topic bridges computational chemistry, structural biology, and microbiology. However, the manuscript is written primarily for a computational audience and does not adequately contextualize the findings for experimentalists or clinicians. The lack of experimental validation limits the appeal to a broader readership.

**Technical soundness:** The technical soundness is currently inadequate. The binding free energy calculations produce implausible values, the MD simulation analysis lacks statistical rigor, and the computational mutagenesis is underdeveloped. The manuscript does not provide sufficient methodological detail to assess the validity of the results.

**Readability for nonspecialists:** The manuscript is reasonably well-structured and the writing is generally clear. However, the discussion of computational methods assumes familiarity with MD simulations and MM-PBSA calculations. The abstract is accessible, but the results and discussion sections would benefit from more careful explanation of the significance of the findings for a broader audience.

### Recommendation posture
Currently not established from the provided evidence. The manuscript addresses a relevant topic and employs a reasonable computational workflow, but the technical flaws in the binding energy calculations, the lack of statistical rigor in the MD analyses, the underdeveloped computational mutagenesis, and the overstatement of conclusions prevent the findings from being considered reliable. The authors should be invited to revise the manuscript substantially, addressing the major concerns outlined above, and to provide the missing figures, tables, and methodological details. If the binding energy calculations are corrected and the conclusions are appropriately tempered, the manuscript could potentially be suitable for publication in a specialized computational biology journal, though it would likely not meet the bar for Nature-level impact given the lack of experimental validation.

## Risk / unsupported claims
1. The claim that all compounds "enhance binding affinity compared to the Apo form" is unsupported due to the implausible absolute values of the reported binding free energies and the lack of statistical analysis.
2. The claim that the compounds "effectively inhibit biofilm formation" is unsupported by any experimental data in this study.
3. The claim that computational mutagenesis results "support experimental data" is not directly validated, as no quantitative comparison to the experimental results of Nicod et al. is provided.
4. The claim that disruption of salt bridge interactions leads to reduced DNA binding affinity is plausible but not directly demonstrated; the causal link is inferred from correlated observations.
5. The claim that the compounds "will display similar inhibition mechanisms as savarin" is speculative and not supported by direct comparative analysis.
6. The statement that "all data generated or analyzed during this study are included in this published article" is not verifiable, as the figures and tables are not visible in the provided material.